CTOR News & Events

Revenue of $3.9M during the quarter ended December 31, 2025 reflects sales related to the launch of Lymphir. Cash and cash equivalents totaled $7.3M as of December 31, 2025 .

Q1 consolidated revenue was $3.9M, reflecting initial U.S. sales of Lymphir at Citius Oncology (CTOR). Cash and cash equivalents totaled $7.7M as of December 31, 2025.

Citius Pharmaceuticals (CTXR) reported business and financial results for the fiscal first quarter ended December 31, 2025, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology (CTOR). "I am thrilled to report that we have successfully transitioned to a revenue generating company following Citius Oncology's December 2025 launch of Lymphir. We recorded $3.9 million in revenue during the quarter, reflecting the initial sales at Citius Oncology's nationwide network of distributors. This milestone is the result of years of focused execution designed to translate innovation into tangible value for the cutaneous T-cell community and Citius stakeholders alike. I congratulate the entire Citius team on an outstanding effort to bring Lymphirto market," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma.

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced that it has entered into an exclusive distribution agreement with Uniphar to support access to Lymphir outside the United States. This agreement represents Citius Oncology's third international distribution partnership and further advances the company's strategy to expand global access to Lymphir through established regional partners. Under the terms of the agreement, Uniphar will serve as the exclusive distribution partner for Lymphir in designated international territories in Western and Eastern Europe through country-specific managed access programs, where permitted by local law. Uniphar will oversee market access and distribution activities in selected territories. Citius Oncology will supply finished product and provide ongoing support in accordance with the agreement. Lymphir is not approved for commercial use outside the United States and, where permitted by local law, will be provided in the territories covered by this agreement solely through country-specific managed access programs, which do not constitute marketing authorization or a commercial launch.